Advertisement
Short reports and correspondence| Volume 60, ISSUE 3, P327-329, March 2007

Heterotopic ossification in the sacral pressure ulcer treated with basic fibroblast growth factor: coincidence or side effect?

      Recent advances in molecular researches on wound healing indicate that topical application of growth factors such as platelet derived growth factor (PDGF) or basic fibroblast growth factor (bFGF) is a promising approach for treating chronic ulcers.
      • Schultz G.S.
      • Sibbald R.G.
      • Falanga V.
      • et al.
      Wound bed preparation: a systematic approach to wound management.
      Especially in Japan, recombinant human bFGF was already approved and is now commercially available (Fiblast® by Kaken Pharmaceutical, Tokyo, Japan) and widely used throughout the country for treatment of chronic and pressure ulcers with considerable effectiveness.
      • Aragane Y.
      • Okamoto T.
      • Yajima A.
      • et al.
      Hydroxyurea-induced foot ulcer successfully treated with a topical basic fibroblast growth factor product.
      • Kurokawa I.
      • Hayami J.
      • Kita Y.
      A therapy-resistant chronic leg ulcer treated successfully with topical basic fibroblast growth factor.
      bFGF, a representative of FGF families, promotes wound healing by inducing angiogenesis and stimulating cellular proliferation in the wounds.
      • Werner S.
      • Grose R.
      Regulation of wound healing by growth factors and cytokines.
      However, biological effects of most growth factors are never specific to wound healing, implying that administration of growth factors for wound healing might result in unexpected adverse reactions. We herein report two cases with heterotopic ossification within sacral pressure ulcers treated with bFGF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Plastic, Reconstructive & Aesthetic Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schultz G.S.
        • Sibbald R.G.
        • Falanga V.
        • et al.
        Wound bed preparation: a systematic approach to wound management.
        Wound Repair Regen. 2003; 11: S1-S28
        • Aragane Y.
        • Okamoto T.
        • Yajima A.
        • et al.
        Hydroxyurea-induced foot ulcer successfully treated with a topical basic fibroblast growth factor product.
        Br J Dermatol. 2003; 148: 599-600
        • Kurokawa I.
        • Hayami J.
        • Kita Y.
        A therapy-resistant chronic leg ulcer treated successfully with topical basic fibroblast growth factor.
        J Int Med Res. 2003; 31: 149-151
        • Werner S.
        • Grose R.
        Regulation of wound healing by growth factors and cytokines.
        Physiol Rev. 2003; 83: 835-870
        • Shehab D.
        • Elgazzar A.H.
        • Collier B.D.
        Heterotopic ossification.
        J Nucl Med. 2002; 43: 346-353
        • Nagase T.
        • Nagase M.
        • Hirose S.
        • et al.
        Mutations in fibroblast growth factor receptor 2 gene and craniosynostotic syndromes in Japanese children.
        J Craniofac Surg. 1998; 9: 162-170
        • Yoon S.T.
        • Boden S.D.
        Osteoinductive molecules in orthopaedics: basic science and preclinical studies.
        Clin Orthop. 2002; : 33-43
        • Iwakura A.
        • Tabata Y.
        • Miyao M.
        • et al.
        Novel method to enhance sternal healing after harvesting bilateral internal thoracic arteries with use of basic fibroblast growth factor.
        Circulation. 2000; 102 (III307–III11)